Problems in patient management and the impact of osteoporosis therapy on the incidence of clinical infection

Problems in patient management and the impact of osteoporosis therapy on the incidence of clinical infection

The global diversion of health resources during the COVID-19 pandemic from the provision of routine medical care, and the more frequent and severe course of this infection in older patients justify the need to study the impact of the pandemic on the management of patients with osteoporosis.Aim – to...

Bibliográfalaš dieđut
Váldodahkkit:	O. M. Lesnyak, E. N. Gladkova, K. E. Zotkina, A. L. Grigoryeva, Yu. A. Safonova, O. Yu. Kuznetsova, M. A. Pokhaznikova
Materiálatiipa:	Artihkal
Giella:	Russian
Almmustuhtton:	IMA PRESS LLC 2021-07-01
Ráidu:	Научно-практическая ревматология
Fáttát:	osteoporosis covid-19 denosumab
Liŋkkat:	https://rsp.mediar-press.net/rsp/article/view/3036

Geahča maid

Denosumab is the first gene engineered agent for the treatment of osteoporosis
Dahkki: O A Nikitinskaya, et al.
Almmustuhtton: (2012-09-01)

Incidence of Atypical Femoral Fractures in Patients on Osteoporosis Therapy—A Registry‐Based Cohort Study
Dahkki: Judith Everts‐Graber, et al.
Almmustuhtton: (2022-10-01)

Current treatment of osteoporosis
Dahkki: Subramanian Nallasivan
Almmustuhtton: (2019-01-01)

Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the Swiss Association against Osteoporosis (SVGO/ASCO)
Dahkki: Christian Meier, et al.
Almmustuhtton: (2017-08-01)

Treatment of patients with osteoporosis: issues of therapy duration, adherence, and replacement
Dahkki: N. V. Toroptsova
Almmustuhtton: (2018-12-01)

Experience with denosumab therapy for osteoporosis in rheumatoid arthritis patients receiving glucocorticoids
Dahkki: I. S. Dydykina, et al.
Almmustuhtton: (2018-06-01)

Case Report: single low-dose of denosumab as a trigger of MRONJ development in a patient with osteoporosis after bisphosphonate therapy
Dahkki: Dávid Száraz, et al.
Almmustuhtton: (2024-12-01)

Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practice
Dahkki: O. V. Dobrovolskaya, et al.
Almmustuhtton: (2019-05-01)

Association of Delayed Denosumab Dosing with Increased Risk of Fractures: A Population-Based Retrospective Study
Dahkki: Kyoung Min Kim, et al.
Almmustuhtton: (2024-12-01)

Monoclonal antibodies in patients with osteoporosis and renal insufficiency: An updated systematic review and meta-analysis
Dahkki: Maria L.R. Defante, et al.
Almmustuhtton: (2024-06-01)

Role of Denosumab and Zoledronic Acid in Geriatric Hip Fractures – A Comparative Analysis
Dahkki: P Madhuchandra, et al.
Almmustuhtton: (2024-01-01)

Efficacy evaluation of denosumab in the treatment of patients with postmenopausal osteoporosis at high risk of fracture
Dahkki: Jing ZHOU, et al.
Almmustuhtton: (2025-02-01)

Advances in the Study of Denosumab Treatment for Osteoporosis and Sarcopenia in the Chinese Middle-Aged and Elderly Population
Dahkki: Li S, et al.
Almmustuhtton: (2024-12-01)

Adherence to treatment with denosumab, its efficacy and safety in women with postmenopausal osteoporosis in clinical practice
Dahkki: N. V. Toroptsova, et al.
Almmustuhtton: (2016-01-01)

A Multi-Center Observation Study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in Patients with Osteoporosis, and Other Non-Malignant Bone Diseases, in Northwestern Italy over 16 Years
Dahkki: Dora Karimi, et al.
Almmustuhtton: (2024-09-01)

THREE YEARS' EXPERIENCE WITH THE BIOLOGICAL AGENT DENOSUMAB USED TO TREAT WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS: EFFICACY, SAFETY AND TREATMENT ADHERENCE
Dahkki: N. V. Toroptsova, et al.
Almmustuhtton: (2017-07-01)

Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis
Dahkki: Jia Yang, et al.
Almmustuhtton: (2024-09-01)

Cellular and molecular mechanisms of osteoporosis: current concepts and future direction treatment
Dahkki: A. T. Dolzhenko, et al.
Almmustuhtton: (2016-06-01)

Cancer treatment-induced bone loss
Dahkki: Yong Jun Choi
Almmustuhtton: (2024-09-01)

Correction of mineral and bone disorders in a patient with long-standing diabetes mellitus type 1 on hemodialysis therapy
Dahkki: Igor A. Sklyanik, et al.
Almmustuhtton: (2016-07-01)

Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)
Dahkki: N. Yu. Velts, et al.
Almmustuhtton: (2024-07-01)

Generalized osteoporosis of mixed origin with severe compression fractures and pain syndrome
Almmustuhtton: (2013-12-01)

CHANGES OF CLINICAL AND RADIOGRAPHIC PARAMETERS DURING DENOSUMAB THERAPY IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING GLUCOCORTICOIDS: PRELIMINARY RESULTS
Dahkki: P. S. Dydykina, et al.
Almmustuhtton: (2015-09-01)

Incidence of Total Knee Arthroplasty in Older Females with Knee Osteoarthritis and Osteoporosis Treated with Denosumab Compared with Those Treated Using Bisphosphonates: A Population-Based Cohort Study
Dahkki: Tzai-Chiu Yu, et al.
Almmustuhtton: (2024-12-01)

Effectiveness of Short-Term Use Denosumab and Risedronate Using β-Crosslaps and Histopathology as a Parameter in Osteoporotic Rat Model
Dahkki: Afrisya Bimo Siwendro, et al.
Almmustuhtton: (2024-09-01)

Discontinuation of Denosumab: Gradual Decrease in Doses Preserves Half of the Bone Mineral Density Gain at the Lumbar Spine
Dahkki: Michel Laroche, et al.
Almmustuhtton: (2023-07-01)

EFFECT OF DENOSUMAB ON CLINICAL AND RADIOLOGICAL CHANGES IN RHEUMATOID ARTHRITIS: PRELIMINARY RESULTS
Dahkki: P. S. Dydykina, et al.
Almmustuhtton: (2015-04-01)

Pharmacoeconomic aspects of osteoporosis problem: analysis of patients willing to pay for the treatment
Dahkki: Y F Lesnyak, et al.
Almmustuhtton: (2005-02-01)

THE ROLE OF CYTOKINE SYSTEM RANKL-RANK-OPG AND CATHEPSIN K IN THE PATHOGENESIS OF OSTEOPOROSIS: ACHIEVEMENTS AND PERSPECTIVES IN THE TREATMENT OF DISEASE
Dahkki: S. Sagalovsky, et al.
Almmustuhtton: (2015-10-01)

Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessment
Dahkki: Chiao-Ling Chen, et al.
Almmustuhtton: (2024-12-01)

Target approach to treating osseous system pathology
Dahkki: M. B. Stenina, et al.
Almmustuhtton: (2014-08-01)

Glucocorticoids: A review of its adverse effects including bone loss
Dahkki: Amit Dua, et al.
Almmustuhtton: (2019-01-01)

Impact of anti-fracture medications on bone material and strength properties: a systematic review and meta-analysis
Dahkki: Shivani Sharma, et al.
Almmustuhtton: (2024-08-01)

Comparison of Denosumab with Romosozumab in the treatment of male osteoporosis: a retrospective cohort study
Dahkki: Tomonori Kobayakawa, et al.
Almmustuhtton: (2024-10-01)

Influence of loop diuretics on denosumab-induced hypocalcaemia in osteoporosis: a retrospective observational analysis
Dahkki: Toshinori Hirai, et al.
Almmustuhtton: (2024-09-01)

A Real‐world Study of Denosumab For Reducing Refracture Risk after Percutaneous Vertebral Augmentation
Dahkki: Jun Zou, et al.
Almmustuhtton: (2024-08-01)

Impact of Teriparatide and Denosumab on Clinical and Radiographic Outcomes in Osteoporotic Vertebral Compression Fractures
Dahkki: Byung-Taek Kwon, et al.
Almmustuhtton: (2024-08-01)

Osteoporosis /
Dahkki: 347485 Compston, Juliet, et al.
Almmustuhtton: (2002)

Osteoporosis
Dahkki: Marcus, Robert, 1940-
Almmustuhtton: (2008)

Economic aspects of complicated osteoporosis: The cost of treatment in the first year after fracture
Dahkki: O. V. Dobrovolskaya, et al.
Almmustuhtton: (2016-09-01)